The EveryLife Foundation has submitted formal comments to the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) regarding proposed changes to the nomination process for the Recommended Uniform Screening Panel (RUSP). These comments focus on mitigating potential adverse effects on rare disease communities, particularly those with small patient populations.
The EveryLife Foundation advocates for modifications to improve the evidence collection process, stressing the need for flexibility in accepting international data and robust support for patient advocacy organizations involved in data gathering. Additionally, the comments emphasize the indispensable role of newborn screening in early diagnosis and intervention, advocating for sustained enhancement and support of these crucial public health initiatives to ensure timely treatment and better health outcomes for newborns with rare conditions.
Read the full comments here.
Related Articles
- The EveryLife Foundation Submits Comments to Support Patient-Focused Drug Development and Medical Innovation
- EveryLife Foundation Urges CDC to Adopt Streamlined, Patient‑Centered Process for ICD‑10 Codes for Rare and Genetic Diseases
- The EveryLife Foundation Submitted Comments on the Plausible Mechanism Framework
